Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Study Linking Supplements, Mortality Sparks Questions On Safety, Oversight

This article was originally published in The Tan Sheet

Executive Summary

A study linking higher mortality with common dietary supplements triggers criticism about the products’ safety and how they are regulated.

You may also be interested in...



Research & Development In Brief: multivitamin may cut breast cancer deaths, vitamin D may lower cancer risk in nonsmoking women, reduce hospital infections, supplementation could shorten hospital stays

Multivitamin/mineral may reduce breast cancer deaths; vitamin D may lower cancer risk in nonsmoking women; vitamin D supplementation could reduce hospital infections; and supplementation could reduce hospital stay duration.

Research & Development In Brief: multivitamin may cut breast cancer deaths, vitamin D may lower cancer risk in nonsmoking women, reduce hospital infections, supplementation could shorten hospital stays

Multivitamin/mineral may reduce breast cancer deaths; vitamin D may lower cancer risk in nonsmoking women; vitamin D supplementation could reduce hospital infections; and supplementation could reduce hospital stay duration.

Groups Defend Supplement Safety After Study Shows Higher Mortality Risk

Supplement industry trade groups argue a study that questions the long-term safety of supplements makes unwarranted recommendations.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS105361

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel